Investment Choices in Digital Drug Discovery Transformation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Source: Fool
- Recursion's Growth Potential: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% year-over-year increase, despite a substantial net loss of approximately $644.8 million, highlighting the high costs and risks associated with drug discovery.
- Schrödinger's Steady Performance: Schrödinger generated about $255.9 million in revenue for FY 2025, marking a 23.3% increase, with a net loss of roughly $103.3 million, indicating stable growth in its software business and improved financial health.
- Risks and Challenges: Recursion faces significant regulatory hurdles and relies heavily on a small number of partners, meaning that the termination of agreements with companies like Roche could severely impact its revenue, while Schrödinger's dependence on unpredictable software sales cycles may affect revenue stability.
- Valuation Comparison: Recursion trades at a price-to-sales ratio of 26.1x, significantly higher than Schrödinger's 4.3x, reflecting a market premium on its future potential, but also indicating a higher investment risk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SDGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SDGR
Wall Street analysts forecast SDGR stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 17.000
Low
18.00
Averages
21.83
High
25.00
Current: 17.000
Low
18.00
Averages
21.83
High
25.00
About SDGR
Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Senseonics Shares Surge 6.1% Amid Strong Volume and Partnership News
- Price Surge Reason: Senseonics Holdings saw a 6.1% increase in its stock price to close at $5.72, with trading volume significantly exceeding normal levels, indicating strong market optimism about its future performance.
- Partnership Announcement: The company partnered with AI health solutions leader Welldoc to develop a custom mobile application for Eversense 365, which has bolstered investor confidence and contributed to the stock price increase.
- Financial Performance: In Q1 2026, Senseonics reported an impressive 87% year-over-year revenue growth and a 35% increase in gross margin, showcasing its robust growth potential in the medical technology sector.
- Future Outlook: Although the upcoming quarterly report is expected to show a loss of $0.55 per share, revenues are projected to reach $13.08 million, up 96.7% year-over-year, indicating the company's strong competitive position and growth prospects in the market.
See More
Schrodinger Inc's Positive Outlook and Growth Potential
- Positive Investment Outlook: The Bill & Melinda Gates Foundation Trust identifies Schrodinger Inc (NASDAQ:SDGR) as one of the best long-term investment stocks, supported by 31 hedge funds, indicating strong market confidence in its future performance.
- Stock Price Uptrend: Schrodinger's shares have risen approximately 13% over the past month, with analysts predicting further upside potential, reflecting investor optimism regarding its transition and growth prospects.
- Revenue Growth Amid Transition: In Q1 2026, Schrodinger reported a 12% year-over-year increase in annual contract value (ACV) to $28.4 million, driven by new deployments and usage scale-ups, despite a 21% decline in software revenue due to the ongoing transition.
- Positive Future Projections: The company anticipates Q2 2026 ACV between $19 million and $23 million, with full-year ACV expected in the range of $218 million to $228 million, reflecting a growth of 10% to 15%, while drug discovery revenue is projected between $55 million and $65 million, indicating strong market demand.
See More
Schrödinger Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On June 12, 2026, Schrödinger granted 10,771 restricted stock units (RSUs) to seven new employees, aimed at attracting talent and enhancing retention, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Conditions: The RSUs will vest over four years, with 25% vesting after 12 months of continuous service and the remaining portion vesting in equal annual installments over the subsequent three years, aligning employee commitment with company growth.
- Company Background: Founded in 1990, Schrödinger focuses on transforming molecular discovery through its computational platform, employing approximately 800 people across 15 global locations, highlighting its influence in the biotechnology and pharmaceutical sectors.
- Technological Advantage: Schrödinger's software platform, built on over 30 years of R&D investment, is licensed by biotechnology, pharmaceutical, and industrial companies as well as academic institutions worldwide, underscoring its leadership in drug development and materials design.
See More
MindWalk Holdings Bets on Biological Knowledge in Drug Discovery
- Importance of Biological Knowledge: MindWalk Holdings Corp. emphasizes that the true value in drug discovery lies in the connectivity of biological knowledge rather than just AI models, a perspective highlighted during the investor panel on June 15, which could influence industry investment directions.
- Technological Innovation: The launch of MindWalk's ReefIQ™ biological context layer technology connects 660 million biological patterns and 25 billion relationships, aiming to enhance AI model accuracy and reduce errors caused by fragmented data, thereby increasing the likelihood of successful drug discovery.
- Financial Performance: In its Q3 fiscal 2026 report, MindWalk reported revenue of CAD 4.2 million, a 52% year-over-year increase, and signed its first annual contract for the LensAI platform, marking a successful transition towards a sustainable revenue model.
- Market Competition: MindWalk faces intense competition in the AI drug discovery space from companies like Absci and Recursion, which tackle similar issues at different layers, and its biological context layer strategy may provide a unique market positioning.
See More
Investment Choices in Digital Drug Discovery Transformation
- Recursion's Growth Potential: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% year-over-year increase, despite a substantial net loss of approximately $644.8 million, highlighting the high costs and risks associated with drug discovery.
- Schrödinger's Steady Performance: Schrödinger generated about $255.9 million in revenue for FY 2025, marking a 23.3% increase, with a net loss of roughly $103.3 million, indicating stable growth in its software business and improved financial health.
- Risks and Challenges: Recursion faces significant regulatory hurdles and relies heavily on a small number of partners, meaning that the termination of agreements with companies like Roche could severely impact its revenue, while Schrödinger's dependence on unpredictable software sales cycles may affect revenue stability.
- Valuation Comparison: Recursion trades at a price-to-sales ratio of 26.1x, significantly higher than Schrödinger's 4.3x, reflecting a market premium on its future potential, but also indicating a higher investment risk.
See More
Comparing AI Pioneers in Drug Discovery
- Revenue Growth Comparison: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% increase, yet it faced a staggering net loss of approximately $644.8 million, highlighting the high costs associated with clinical trials and digital infrastructure, leaving its future profitability uncertain.
- Software Revenue Stability: Schrödinger generated around $255.9 million in revenue for FY 2025, marking a 23.3% increase, and while it reported a net loss of roughly $103.3 million, this represents an improvement from the previous year, indicating a gradual stabilization and expansion of its software business.
- Market Risk Analysis: Recursion's reliance on a small number of large partners like Roche and Bayer poses significant revenue risks, as the termination of any agreement could severely impact its income, compounded by competitive pressures from larger firms.
- Divergent Future Outlooks: Although Schrödinger is also currently operating at a loss, management anticipates a significant reduction in operating expenses in 2026, with annual contract value expected to grow by 10% to 15%, suggesting potential growth momentum for its business.
See More
Senseonics Shares Surge 6.1% Amid Strong Volume and Partnership News
- Price Surge Reason: Senseonics Holdings saw a 6.1% increase in its stock price to close at $5.72, with trading volume significantly exceeding normal levels, indicating strong market optimism about its future performance.
- Partnership Announcement: The company partnered with AI health solutions leader Welldoc to develop a custom mobile application for Eversense 365, which has bolstered investor confidence and contributed to the stock price increase.
- Financial Performance: In Q1 2026, Senseonics reported an impressive 87% year-over-year revenue growth and a 35% increase in gross margin, showcasing its robust growth potential in the medical technology sector.
- Future Outlook: Although the upcoming quarterly report is expected to show a loss of $0.55 per share, revenues are projected to reach $13.08 million, up 96.7% year-over-year, indicating the company's strong competitive position and growth prospects in the market.
See More
Schrodinger Inc's Positive Outlook and Growth Potential
- Positive Investment Outlook: The Bill & Melinda Gates Foundation Trust identifies Schrodinger Inc (NASDAQ:SDGR) as one of the best long-term investment stocks, supported by 31 hedge funds, indicating strong market confidence in its future performance.
- Stock Price Uptrend: Schrodinger's shares have risen approximately 13% over the past month, with analysts predicting further upside potential, reflecting investor optimism regarding its transition and growth prospects.
- Revenue Growth Amid Transition: In Q1 2026, Schrodinger reported a 12% year-over-year increase in annual contract value (ACV) to $28.4 million, driven by new deployments and usage scale-ups, despite a 21% decline in software revenue due to the ongoing transition.
- Positive Future Projections: The company anticipates Q2 2026 ACV between $19 million and $23 million, with full-year ACV expected in the range of $218 million to $228 million, reflecting a growth of 10% to 15%, while drug discovery revenue is projected between $55 million and $65 million, indicating strong market demand.
See More
Schrödinger Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On June 12, 2026, Schrödinger granted 10,771 restricted stock units (RSUs) to seven new employees, aimed at attracting talent and enhancing retention, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Conditions: The RSUs will vest over four years, with 25% vesting after 12 months of continuous service and the remaining portion vesting in equal annual installments over the subsequent three years, aligning employee commitment with company growth.
- Company Background: Founded in 1990, Schrödinger focuses on transforming molecular discovery through its computational platform, employing approximately 800 people across 15 global locations, highlighting its influence in the biotechnology and pharmaceutical sectors.
- Technological Advantage: Schrödinger's software platform, built on over 30 years of R&D investment, is licensed by biotechnology, pharmaceutical, and industrial companies as well as academic institutions worldwide, underscoring its leadership in drug development and materials design.
See More
MindWalk Holdings Bets on Biological Knowledge in Drug Discovery
- Importance of Biological Knowledge: MindWalk Holdings Corp. emphasizes that the true value in drug discovery lies in the connectivity of biological knowledge rather than just AI models, a perspective highlighted during the investor panel on June 15, which could influence industry investment directions.
- Technological Innovation: The launch of MindWalk's ReefIQ™ biological context layer technology connects 660 million biological patterns and 25 billion relationships, aiming to enhance AI model accuracy and reduce errors caused by fragmented data, thereby increasing the likelihood of successful drug discovery.
- Financial Performance: In its Q3 fiscal 2026 report, MindWalk reported revenue of CAD 4.2 million, a 52% year-over-year increase, and signed its first annual contract for the LensAI platform, marking a successful transition towards a sustainable revenue model.
- Market Competition: MindWalk faces intense competition in the AI drug discovery space from companies like Absci and Recursion, which tackle similar issues at different layers, and its biological context layer strategy may provide a unique market positioning.
See More
Investment Choices in Digital Drug Discovery Transformation
- Recursion's Growth Potential: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% year-over-year increase, despite a substantial net loss of approximately $644.8 million, highlighting the high costs and risks associated with drug discovery.
- Schrödinger's Steady Performance: Schrödinger generated about $255.9 million in revenue for FY 2025, marking a 23.3% increase, with a net loss of roughly $103.3 million, indicating stable growth in its software business and improved financial health.
- Risks and Challenges: Recursion faces significant regulatory hurdles and relies heavily on a small number of partners, meaning that the termination of agreements with companies like Roche could severely impact its revenue, while Schrödinger's dependence on unpredictable software sales cycles may affect revenue stability.
- Valuation Comparison: Recursion trades at a price-to-sales ratio of 26.1x, significantly higher than Schrödinger's 4.3x, reflecting a market premium on its future potential, but also indicating a higher investment risk.
See More
Comparing AI Pioneers in Drug Discovery
- Revenue Growth Comparison: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% increase, yet it faced a staggering net loss of approximately $644.8 million, highlighting the high costs associated with clinical trials and digital infrastructure, leaving its future profitability uncertain.
- Software Revenue Stability: Schrödinger generated around $255.9 million in revenue for FY 2025, marking a 23.3% increase, and while it reported a net loss of roughly $103.3 million, this represents an improvement from the previous year, indicating a gradual stabilization and expansion of its software business.
- Market Risk Analysis: Recursion's reliance on a small number of large partners like Roche and Bayer poses significant revenue risks, as the termination of any agreement could severely impact its income, compounded by competitive pressures from larger firms.
- Divergent Future Outlooks: Although Schrödinger is also currently operating at a loss, management anticipates a significant reduction in operating expenses in 2026, with annual contract value expected to grow by 10% to 15%, suggesting potential growth momentum for its business.
See More
